Unicorn Capital Partners

The company provides financial services other than insurance and pension services.

2022: Investing in the developer of the drug for the treatment of arterial hypertension "Target Medicals"

On February 1, 2022, it was announced that it was investing in Target Medicines. The Russian Direct Investment Fund (RDIF), the pharmaceutical giant AstraZeneca and Unicorn Capital Partners (the managing company of the PharmMed Innovation venture fund) invested in the developer of the drug for the treatment of hypertension. More details here.

2020: Investing in Intellojik

The company "Intellojik" attracted 160 million rubles of investment in the framework of round B. This was announced by the Skolkovo Fund on December 23, 2020. The lead investor was Unicorn Capital Partners. More details here.

2019: Victory in the selection of RVC for the management of a fund for high-tech medical projects

On December 18, 2019, the RVC informed Zdrav.Expert that it had determined the winner of the selection for the management of a fund for high-tech medical projects.

According to the results of the open selection, the Unicorn Capital Partners investment team scored the most points. The Fund is created by the RVC together with the Ministry of Industry and Trade of the Russian Federation for investments in high-tech projects in the production of innovative medicines, medical products and software.

RVC announced an open selection for the search for a managing comrade for a venture fund in the field pharmaceutical and medical industries in July 2019. In total, three applications were submitted for open selection. The evaluation of applications from applicants was carried out by a commission with the participation of leading experts from specialized corporations, universities and development institutions and representatives of the RVC. The Commission evaluated such criteria as the proposal of the main terms of the investment partnership agreement, the proposal for the investment strategy of the fund and its financial model, as well as the list of projects proposed for priority investment. Particular attention was paid to the qualifications and experience of the management team in investing in various segments of the pharmaceutical and medical market. As part of the interview stage, the selection participants made a full-time presentation of their proposals and answered the questions of the commission. Following the selection results, the Board of Directors of the RVC recognized the Unicorn Capital Partners team as the winner.

The fund will be created in the form of an investment partnership for a period of 10 years, the investment period will be 5 years. The contribution of RVC to the capital of this fund will be 4.5 billion rubles. The technological priorities of the fund will be aimed at creating drugs and means of delivering drugs, developing high-tech medical products and software in medicine. The Fund will invest in Russian and foreign projects of early stages A, B, B + (phase I and II clinical trials for drugs), sowing stages and at the preclinical stage.

By creating this venture fund, the state demonstrates its readiness to create tools for return financing and support using market mechanisms for targeted support of the most promising teams, technologies and projects. The winner was a team of professional market players with deep expertise and specialized experience. It is important to note that the management company undertakes to attract private co-investments to the capital of the fund or portfolio companies in an amount not less than that to be provided by the RVC, noted Deputy General Director - Investment Director of RVC Alexey Basov

The state consistently supports high-tech startups in the most strategically important areas for the country, which, of course, include medicine and pharmaceuticals. We are grateful to the RVC and the selection committee for the high assessment of our application and team. Together with our expert council, we will do everything possible to ensure the effective investment of the fund's funds in the best innovative projects, and we invite applicants to come to the fund. The importance and complexity of the tasks facing us is difficult to overestimate, but we believe that thanks to the financial and organizational support of the RVC and the Ministry of Industry and Trade of the Russian Federation, the fund will form a strong innovative portfolio, said CEO of Unicorn Capital Partners Alexei Vinogradov